Hyperoncotic colloids and acute kidney injury: a meta-analysis of randomized trials

Department of Internal Medicine, Central Hospital of Bolzano, Lorenz Böhler Street 5, 39100 Bolzano, Italy.
Critical care (London, England) 10/2010; 14(5):R191. DOI: 10.1186/cc9308
Source: PubMed

ABSTRACT It has been hypothesized that hyperoncotic colloids might contribute to acute kidney injury (AKI). However, the validity of this hypothesis remains unclear.
A meta-analysis was conducted of randomized controlled trials evaluating AKI after infusion of hyperoncotic albumin and hydroxyethyl starch (HES) solutions. Mortality was a secondary endpoint. Eligible trials were sought by multiple methods, and the pooled odds ratios (OR) for AKI and death and 95% confidence intervals (CI) were computed under a random effects model.
Eleven randomized trials with a total of 1220 patients were included: 7 evaluating hyperoncotic albumin and 4 hyperoncotic HES. Clinical indications were ascites, surgery, sepsis and spontaneous bacterial peritonitis. Hyperoncotic albumin decreased the odds of AKI by 76% (OR, 0.24; CI, 0.12-0.48; P < 0.0001), while hyperoncotic HES increased those odds by 92% (OR, 1.92; CI, 1.31-2.81; P = 0.0008). Parallel effects on mortality were observed, with hyperoncotic albumin reducing the odds of death by 48% (OR, 0.52; CI, 0.28-0.95; P = 0.035) and hyperoncotic HES raising those odds by 41% (OR, 1.41; CI, 1.01-1.96; P = 0.043).
This meta-analysis does not support the hypothesis that hyperoncotic colloid solutions per se injure the kidney. Renal effects appear instead to be colloid-specific, with albumin displaying renoprotection and HES showing nephrotoxicity.


Available from: Christian Josef Wiedermann, Apr 15, 2014
  • [Show abstract] [Hide abstract]
    ABSTRACT: L’albumine est une macromolécule de forme monocaténaire, très soluble, à charge négative, pouvant se lier aux cations et aux anions. C’est une protéine multifonctionnelle, qui joue un rôle essentiel dans la physiologie et la détoxification, notamment par sa spécificité de ligand et sa capacité à lier un grand nombre de substances endogènes ou exogènes, comme les médicaments. L’albumine humaine est le principal déterminant de la pression oncotique et constitue un produit d’expansion volémique. Comparé à d’autres solutés de remplissage, il s’agit d’un produit dérivé du sang et coûteux. Même si l’usage de l’albumine semble sûr en termes d’effets hémodynamiques, de fonction rénale et de survie, son bénéfice comme produit de remplissage dans le choc septique est sujet à controverses et les données de la littérature, expérimentales et cliniques, sont contradictoires. L’albumine humaine possède enfin des propriétés antioxydantes et modulatrices de l’inflammation, qui permettent de diminuer la perméabilité capillaire. Sa présentation plasmatique sous forme réduite avec un groupement thiol libre, en grande partie à l’origine de ses propriétés antioxydantes, permet à l’albumine humaine de moduler potentiellement l’inflammation et le stress oxydant, la rendant ainsi bénéfique dans le choc septique, notamment via une amélioration de la dysfonction endothéliale. L’albumine serait aussi moins pro-inflammatoire que d’autres solutés de remplissage vasculaire, car elle diminue l’activation, l’extravasation et l’infiltration des neutrophiles au niveau tissulaire. Ces propriétés semblent être dose-dépendantes. Cette revue propose une actualisation des connaissances sur les caractéristiques et propriétés de l’albumine et son indication dans le traitement du sepsis et du choc septique. Abstract Albumin is a multifunctional protein which plays a major role in physiology, drugs pharmacokinetics, and detoxication, partly due to its ligand specificity and its ability to bind a large number of endogenous and exogenous substances. Albumin is the main determinant of oncotic pressure and is therefore used for volume expansion in hypovolemia, shock, burns, liver failure or chronic liver disease, and denutrition. If albumin appears to be safe as far as hemodynamic effects, renal function and survival are concerned, its benefice as fluid expander in septic shock is controversial and experimental as well as clinical data are contradictory. Compared to other plasma expanders, it is a blood-derived and expensive product. Albumin would finally have antioxidative properties and modulate inflammation, thus decreasing capillary permeability. Human albumin is indeed involved in the inflammatory and oxidative stress pathways modulation and may thus be beneficial in septic shock, through improvement of endothelial dysfunction. Albumin is also less pro-inflammatory than other plasma expanders, decreasing neutrophils activation and infiltration. It would even exhibit immunosuppressive effects. All these properties seem to be dose-dependent. In severe sepsis, albumin could be useful for fluid resuscitation and as an antioxidative or anti-inflammatory adjuvant therapy. Albumin use for volume expansion is controversial, as experimental and clinical data diverge. Albumin is more expansive and at risk of blood pathogens transmission compared to cristalloids and other colloids. This review provides an update on albumin characteristics and properties and albumin indication in the treatment of sepsis and septic shock.
    Réanimation 03/2013; 23(2):148-158. DOI:10.1007/s13546-013-0834-4
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We summarize the emerging new literature regarding the pathophysiological principles underlying the beneficial and deleterious effects of fluid administration during resuscitation, as well as current recommendations and recent clinical evidence regarding specific colloids and crystalloids. This systematic review allows us to conclude that there is no clear benefit associated with the use of colloids compared to crystalloids and no evidence to support the unique benefit of albumin as a resuscitation fluid. Hydroxyethyl starch use has been associated with increased acute kidney injury (AKI) and use of renal replacement therapy. Other synthetic colloids (dextran and gelatins) though not well studied do not appear superior to crystalloids. Normal saline (NS) use is associated with hyperchloremic metabolic acidosis and increased risk of AKI. This risk is decreased when balanced salt solutions are used. Balanced crystalloid solutions have shown no harmful effects, and there is evidence for benefit over NS. Finally, fluid resuscitation should be applied in a goal-directed manner and targeted to physiologic needs of individual patients. The evidence supports use of fluids in volume-responsive patients whose end-organ perfusion parameters have not been met.
    12/2014; 4:38. DOI:10.1186/s13613-014-0038-4
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Early fluid resuscitation is vital to patients with sepsis. However, the choice of fluid has been a hot topic of discussion. The objective of this study was to evaluate whether the use of albumin-containing fluids for resuscitation in patients with sepsis was associated with a decreased mortality rate. We systematically searched PubMed, EMBASE and Cochrane library for eligible randomized controlled trials (RCTs) up to March 2014. The selection of eligible studies, assessment of methodological quality, and extraction of all relevant data were conducted by two authors independently. In total, 15 RCTs were eligible for analysis. After pooling the data, we found there was no significant effect of albumin-containing fluids on mortality in patients with sepsis of any severity (RR: 0.94, 95% CI: 0.87, 1.02 and RD: -0.01, 95% CI: -0.03, 0.01). The results were robust to subgroup analyses, sensitivity analyses and trial sequential analyses. The present meta-analysis did not demonstrate significant advantage of using albumin-containing fluids for resuscitation in patients with sepsis of any severity. Given the cost-effectiveness of using albumin, crystalloids should be the first choice for fluid resuscitation in septic patients.
    PLoS ONE 12/2014; 9(12):e114666. DOI:10.1371/journal.pone.0114666 · 3.53 Impact Factor